Immunocore logo

Immunocore

IMCR | NASDAQ
Chart Builder DCF Calculator
$28.88
-$1.06 (-3.54%)
At close: Nov 16, 2026, 4:00 PM ET
$28.88
$0.00 (0.00%)
After-hours: Nov 16, 2026, 6:41 PM ET
-3.54%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
45.2
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #382/1021 (Top 37%)

Key Statistics

Market Data

Market Cap $1.49B
1D Range
28.77 30.37
52W Range
27.79 40.22

Valuation (TTM)

PE -58.94
PB 3.55
EV/EBITDA -476.37

Valuation (NTM)

Forward PE N/A
Forward PEG 1.67
Price Target $39.00
Loading financial charts...

Profile

Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The compa...

Sector Healthcare
Industry Biotechnology
Employees 524
IPO Date Feb 5, 2021
Fiscal Year January - December

Latest News

Immunocore to present at upcoming investor conferences

8 days ago · globenewswire.com

Immunocore to present at upcoming investor conferences
Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma

11 days ago · globenewswire.com

Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
Immunocore reports third quarter financial results and provides a business update

11 days ago · globenewswire.com

Immunocore reports third quarter financial results and provides a business update
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

19 days ago · globenewswire.com

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

1 month ago · globenewswire.com

Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study

2 months ago · zacks.com

Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

2 months ago · globenewswire.com

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?

3 months ago · zacks.com

Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum

3 months ago · zacks.com

IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum

Earnings

Latest Earnings
Nov 6, 2026
EPS
-$0.28
Miss -133.33%
REV
$102.22M
Miss -32.79%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
4
Consensus
Hold
Price Target
$39.00
Upside
+35.04%
Buy (2)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.